Antoni Ribas, MD, PhD

New Capabilities

Framing LUT014's expansion across MAPK-pathway inhibitors

Colorectal cancer patients on EGFR inhibitors often develop painful, cherry-red acneiform rashes. A third of them cut back or pause their cancer therapy because of it. Lutris Pharma's experimental gel reduced that non-adherence rate to 10.3%, down from 28.2% with placebo, in a 118-patient Phase 2 trial.

Updated 2 hours ago